The pharmacological management of erectile dysfunction – Update 2016

Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	André Marais
Formato:	article
Lenguaje:	EN
Publicado:	AOSIS 2016
Materias:	cardiovascular disease erectile dysfunction phosphodiesterase-5 inhibitors prostaglandin testosterone Medicine R
Acceso en línea:	https://doaj.org/article/ac2c0879c48f4050a954caea45b7c80c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac2c0879c48f4050a954caea45b7c80c
record_format	dspace
spelling	oai:doaj.org-article:ac2c0879c48f4050a954caea45b7c80c2021-11-24T07:44:18ZThe pharmacological management of erectile dysfunction – Update 20162078-61902078-620410.4102/safp.v58i4.4521https://doaj.org/article/ac2c0879c48f4050a954caea45b7c80c2016-08-01T00:00:00Zhttps://safpj.co.za/index.php/safpj/article/view/4521https://doaj.org/toc/2078-6190https://doaj.org/toc/2078-6204Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future, available drugs used in the management of ED.André MaraisAOSISarticlecardiovascular diseaseerectile dysfunctionphosphodiesterase-5 inhibitorsprostaglandintestosteroneMedicineRENSouth African Family Practice, Vol 58, Iss 4, Pp 10-14 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiovascular disease erectile dysfunction phosphodiesterase-5 inhibitors prostaglandin testosterone Medicine R
spellingShingle	cardiovascular disease erectile dysfunction phosphodiesterase-5 inhibitors prostaglandin testosterone Medicine R André Marais The pharmacological management of erectile dysfunction – Update 2016
description	Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future, available drugs used in the management of ED.
format	article
author	André Marais
author_facet	André Marais
author_sort	André Marais
title	The pharmacological management of erectile dysfunction – Update 2016
title_short	The pharmacological management of erectile dysfunction – Update 2016
title_full	The pharmacological management of erectile dysfunction – Update 2016
title_fullStr	The pharmacological management of erectile dysfunction – Update 2016
title_full_unstemmed	The pharmacological management of erectile dysfunction – Update 2016
title_sort	pharmacological management of erectile dysfunction – update 2016
publisher	AOSIS
publishDate	2016
url	https://doaj.org/article/ac2c0879c48f4050a954caea45b7c80c
work_keys_str_mv	AT andremarais thepharmacologicalmanagementoferectiledysfunctionupdate2016 AT andremarais pharmacologicalmanagementoferectiledysfunctionupdate2016
_version_	1718415877895880704

The pharmacological management of erectile dysfunction – Update 2016

Ejemplares similares